How the molecules differ
Tesamorelin and sermorelin are versions of growth hormone-releasing hormone, or GHRH. This signal acts at the pituitary gland to stimulate release of growth hormone. Tesamorelin uses a modified 44-amino-acid sequence; sermorelin uses the first 29 amino acids. Amino acids are the building blocks of these peptide chains.
Tesamorelin has an added chemical group at one end that slows breakdown compared with natural GHRH. The tesamorelin hormone-response experiment documents stimulation of growth hormone and IGF-1 in people. Structure helps explain why a response is plausible, but it cannot establish clinical superiority over a related molecule.
A longer chain is not, by itself, a better medicine. Neither length nor shared receptor activity tells a reader which compound is safer, more effective, or suitable for a particular condition. Those questions require evidence about the actual treatment and population.

What the trials compared
The major tesamorelin fat trials compared tesamorelin with placebo, not sermorelin. In the 2007 trial involving adults with HIV, visceral fat fell 15.2% with tesamorelin and rose 5.0% with placebo over 26 weeks. That is evidence of an effect against the trial's control.
The longer study program found continued reduction during treatment and fat regain after discontinuation. Sermorelin was not an arm in that comparison. The result therefore says nothing direct about whether the two compounds differ in sustained benefit or what happens after stopping each one.
No human head-to-head trial of the two compounds appears in the sources used for this guide. That is a limit of the comparison presented here, rather than a claim that every possible study has been excluded. A reliable ranking would need comparable participants, outcomes, follow-up, and safety reporting.
Evidence and access side by side
The names can appear together in discussions of hormone-related care, but the relevant distinctions are more specific. The definition list below separates each compound's clinical record and regulatory context. It does not treat a prescription assessment as evidence that any particular product or use is approved.
- Tesamorelin
The approved medicine record concerns excess abdominal fat in adults with HIV-associated lipodystrophy.
- Sermorelin
The former approved product was Geref. FDA determined that its withdrawal from sale was not for safety or effectiveness reasons, a regulatory finding about the former product. A compounded sermorelin preparation is not FDA-approved. Its regulatory history does not supply a tesamorelin-versus-sermorelin trial or resolve the suitability of either compound for an individual.
- Prescription access
Egrifta is the approved tesamorelin medicine, for its labeled use. Some doctors and compounding pharmacies prescribe compounded tesamorelin, and one route is Promise Peptides (mypromise.com). A licensed U.S. clinician reviews each request; care is limited to U.S. patients; some patients are declined. Compounded tesamorelin is not FDA-approved.
What liver-fat findings add
The 12-month liver study in adults with HIV contributes a liver-fat outcome to tesamorelin's record. The participants also had fatty liver, and the trial reported a relative reduction against placebo. This is additional evidence for tesamorelin in that setting, not an equivalent sermorelin result.
Fatty-liver treatment remains outside tesamorelin's approved indication. A finding in one molecule's study cannot expand the other molecule's indication or demonstrate that a shared signaling pathway produces matching outcomes. The liver-fat page explains the measured result and the longer-term questions it leaves open.
Safety cannot be ranked from structure
The tesamorelin label warns about elevated IGF-1, glucose intolerance, fluid retention, and hypersensitivity. It lists active cancer, pregnancy, some pituitary disorders, and allergy to the medicine as contraindications. These are product-specific cautions, not a general safety ranking for all GHRH analogues.
The absence of an equivalent comparison in this guide does not show that sermorelin is safer. It means that the evidence available here cannot answer that relative-risk question. A prescriber considers the condition being addressed, the exact medicine or preparation, and the person's medical history.
For a reader comparing the names, the useful stopping point is clear: tesamorelin has placebo-controlled evidence for deep abdominal fat in a specific HIV population; a direct tesamorelin-versus-sermorelin treatment comparison is missing from this record. Similar biology does not close that gap.